Riverside acquires iTakeControl of Pennsylvania as latest add-on for Red Nucleus platform
Print
The Riverside Co. has acquired iTakeControl, a Malvern, Pa.-based provider of clinical operations and medical affairs technology and services focused on rare disease and specialty pharma, as an add-on to its Red Nucleus platform company.
Terms of the deal were not disclosed.
The transaction marks the fourth add-on deal related to the platform since an initial investment in December 2019.
"This partnership will provide Red Nucleus with a new, differentiated SaaS technology product undergoing significant growth in the marketplace," said Peter Tsang, Riverside co-chief investment officer for Riverside Capital Appreciation Fund, in a statement. "Working with the ITC team, we plan to expand our suite of software products with the company's virtual clinical software platform and leverage Red Nucleus' learning expertise to deliver education programs for clinical trial patients via ITC's platform."